Precision Treatment for Triple-Negative Breast Cancer in Shanghai
Triple-negative breast cancer (TNBC) is the most aggressive and difficult-to-treat subtype of breast cancer, accounting for approximately 15–20% of all cases. It lacks estrogen receptors, progesterone receptors, and HER2 overexpression — making it unresponsive to hormonal therapies and standard targeted agents. For international patients seeking the most advanced TNBC care, Shanghai is now home to globally recognized research and precision treatment protocols.
Featured Specialist: Prof. Jiang Yizhou (江一舟)
Prof. Jiang Yizhou is a leading breast oncologist at Fudan University Shanghai Cancer Center (FUSCC) — China's premier dedicated cancer hospital and one of Asia's most respected oncology institutions.
Prof. Jiang is the architect of the groundbreaking "Fudan Classification" (复旦分型) system — a molecular subtyping framework that redefines how triple-negative breast cancer is diagnosed and treated at the individual patient level. This precision oncology approach has transformed outcomes for patients with refractory TNBC:
- Traditional chemotherapy regimens achieved a response rate of approximately 10% in refractory TNBC
- Fudan Classification-guided individualized therapy raised response rates to 29.8% — nearly tripling treatment effectiveness
Prof. Jiang's work has earned him the 2025 New Era Young Pioneer Award, one of China's most prestigious recognitions for young scientific leaders. His research is published in leading international journals and is actively shaping global TNBC treatment guidelines.
What Is the Fudan Classification?
The Fudan Classification divides triple-negative breast cancer into four distinct molecular subtypes, each with a different biological driver and optimal treatment strategy:
- LAR (Luminal androgen receptor): Responds to androgen receptor-targeted therapy
- MES (Mesenchymal): Benefits from PI3K/mTOR pathway inhibitors
- BLIS (Basal-like immune-suppressed): May respond to PARP inhibitors and DNA damage agents
- IM (Immunomodulatory): Strong candidate for PD-1/PD-L1 immunotherapy
By identifying which subtype a patient has — through comprehensive molecular profiling of tumor tissue — Prof. Jiang's team can design a personalized treatment plan rather than applying a one-size-fits-all chemotherapy protocol.
Treatment Options at Fudan University Shanghai Cancer Center
- Molecular tumor profiling using the Fudan Classification system
- Subtype-guided chemotherapy with optimized drug selection
- Immunotherapy (PD-1/PD-L1 inhibitors) for IM subtype patients
- PARP inhibitors for BRCA-mutated or BLIS subtype TNBC
- Androgen receptor inhibitors for LAR subtype
- Clinical trial access — FUSCC runs multiple active TNBC trials not available elsewhere
- Neoadjuvant therapy to achieve pathological complete response before surgery
- Breast-conserving surgery and oncoplastic reconstruction
Who Should Consider Coming to Shanghai for TNBC?
- Patients with refractory or recurrent TNBC who have not responded to standard chemotherapy
- Patients seeking molecular subtyping to guide treatment decisions
- Patients interested in clinical trial participation for novel TNBC agents
- Patients who want a second opinion from a world-leading TNBC specialist
- Patients with BRCA1/2 mutations seeking PARP inhibitor protocols
Why Fudan University Shanghai Cancer Center?
- China's highest-volume dedicated cancer center, treating over 100,000 patients annually
- Home to multiple nationally designated key oncology laboratories
- Active participation in international multi-center clinical trials
- Multidisciplinary breast cancer tumor board with surgeons, medical oncologists, radiation oncologists, pathologists, and geneticists
- Significantly lower treatment costs than equivalent care in the US, UK, or Australia
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We specialize in connecting international patients with Shanghai's top oncology specialists, including Prof. Jiang Yizhou at Fudan University Shanghai Cancer Center.
Our team manages the full patient journey:
- Review and translation of existing pathology reports, imaging, and molecular test results
- Specialist referral to Prof. Jiang's team based on your TNBC profile
- Appointment scheduling with priority access
- Medical interpretation during consultations and tumor board discussions
- Coordination of tissue re-biopsy or molecular profiling if needed
- Logistics support: accommodation, visa assistance, and local transport
- Post-treatment follow-up and remote monitoring coordination
Get in Touch
If you have been diagnosed with triple-negative breast cancer and are exploring advanced treatment options in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개